Beta Bionics, Inc. (BBNX)
2025-06-30 | 2025-03-31 | |||
|---|---|---|---|---|
| Net sales | 23,238 | 17,639 | ||
| Cost of sales | 10,735 | 8,668 | ||
| Gross profit | 12,503 | 8,971 | ||
| Sales and marketing | 15,623 | 13,402 | ||
| Research and development | 8,873 | 7,590 | ||
| General and administrative | 7,879 | 6,621 | ||
| Total operating expenses | 32,375 | 27,613 | ||
| Loss from operations | -19,872 | -18,642 | ||
| Other income (expense), net | -2 | - | ||
| Interest income | 3,005 | 2,436 | ||
| Change in fair value of warrant liabilities | - | 12,450 | ||
| Total other income (expense), net | 3,003 | -10,014 | ||
| Net loss | -16,869 | -28,656 | ||
| Unrealized gain (loss) on short-term investments | -91 | 175 | ||
| Comprehensive loss | -16,960 | -28,481 | ||
| Earnings per share, basic | -0.39 | -0.93 | ||
| Earnings per share, diluted | -0.39 | -0.93 | ||
| Weighted average number of shares outstanding, basic | 43,390,652 | 30,714,769 | ||
| Weighted average number of shares outstanding, diluted | 43,390,652 | 30,714,769 | ||